Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $133.00 Average PT from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $133.00.

A number of equities research analysts have commented on ORKA shares. Wedbush reissued an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. BTIG Research reaffirmed a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 3rd.

Oruka Therapeutics Trading Up 4.5%

Shares of ORKA stock opened at $97.73 on Friday. The company has a market cap of $6.47 billion, a price-to-earnings ratio of -48.14 and a beta of -0.34. The stock has a 50 day simple moving average of $96.24 and a 200-day simple moving average of $73.64. Oruka Therapeutics has a 12-month low of $14.89 and a 12-month high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, equities analysts forecast that Oruka Therapeutics will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Lawrence Klein sold 2,452 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $95.71, for a total value of $234,680.92. Following the sale, the chief executive officer owned 923,128 shares in the company, valued at $88,352,580.88. This represents a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 560 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $95.71, for a total value of $53,597.60. Following the completion of the transaction, the senior vice president directly owned 14,752 shares of the company’s stock, valued at $1,411,913.92. The trade was a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 124,004 shares of company stock worth $11,606,239 in the last quarter. Company insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Several large investors have recently bought and sold shares of ORKA. Nykredit A S acquired a new position in shares of Oruka Therapeutics during the 2nd quarter worth $29,000. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at about $91,000. Natural Investments LLC acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at about $202,000. Caitong International Asset Management Co. Ltd purchased a new position in Oruka Therapeutics during the 4th quarter valued at about $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Oruka Therapeutics during the 2nd quarter valued at about $211,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.